In haemolytic crisis, patients with AIHA often require blood transfusion therapy, but the presence of the patient’s own anti-erythrocyte antibodies in AIHA patients makes blood allocation difficult and makes it more likely that haemolytic transfusion reactions will occur, with some risk. the main pharmacological treatments for AIHA are immunosuppressive agents, including glucocorticoid therapy, which can cause sequelae such as osteoporosis, and rituximab to clear B lymphocytes. The surgical splenectomy treatment approach is partially clinically effective, but is currently used as a third-line treatment option due to and susceptibility to complications such as infection and venous embolism.